Cathepsin B inhibition limits bone metastasis in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metastasis Research

Background:

• Bone metastasis is a significant complication in breast cancer patients, necessitating research into its molecular drivers.
• Stefin A, a cysteine cathepsin inhibitor, suppresses breast cancer bone metastasis and is coexpressed with cathepsin B in bone metastases.

Purpose of the Study:

• To investigate the role of cathepsin B in breast cancer bone metastasis using an immunocompetent 4T1.2 mouse model.
• To evaluate cathepsin B as a therapeutic target for advanced breast cancer with bone metastasis.

Main Methods:

• Utilized the 4T1.2 mouse model of spontaneous bone metastasis.
• Employed RNA interference to knock down cathepsin B expression in tumor cells.
• Administered the selective cathepsin B inhibitor CA-074 and a broad-spectrum inhibitor JPM-OEt in vivo.
• Assessed collagen I degradation in vitro and bone metastasis in vivo.

Main Results:

• Cathepsin B abundance in the 4T1.2 model mirrored human disease in primary tumors and spinal metastases.
• Cathepsin B knockdown reduced collagen I degradation and bone metastasis.
• Selective cathepsin B inhibition with CA-074 significantly reduced metastasis, unlike broad-spectrum inhibition.
• CA-074 demonstrated efficacy even in a late treatment setting, indicating a role in metastatic outgrowth.

Conclusions:

• Cathepsin B plays a pro-metastatic role in the development of distant bone metastases in breast cancer.
• Selective inhibition of cathepsin B represents a promising therapeutic strategy for managing breast cancer bone metastasis.